Interventional cardiology news to note
"Bleeding is never intended, but rarely is it prohibitive. This boy is not that bad," said an editorial commenting on a study of bleeding events in the COMPASS trial of rivaroxaban (Xarelto) and aspirin in coronary and peripheral artery disease. (Journal of the American College of Cardiology)